Loading...

PYXS PYXIS ONCOLOGY INC Expansion Plans 8-K Filing

PYXS

PYXS

PYXIS ONCOLOGY INC

(PYXS)

2025 8-K

CEO Departure Update

Financial Update

Positive Data Release

Quarterly Results

Financial Results Announced

Product Expansion

Financial Statements

Corporate Presentation

Management Change

Trial Initiation

Clinical Program Focus

Clinical Update

Financial Results

Stockholder Meeting

Financial Results

Annual Meeting of Stockholders

Appointment of Director

Earnings Reports

Acquisition of Apexigen, Inc.

Sale of Royalty Rights

Earnings Reports

Appointment of Director

Private Placement

Appointment of Chief Medica...

Financial Results Announcement

Amendment for Acquisition

Completion of Acquisition o...

Earnings Release

Merger Agreement

Board Appointment

Annual Meeting of Stockholders

Conference Call

Merger Agreement

Earnings Reports

Stock Option Repricing

Financial Results and Manag...

Phase 1 trial announcement

External Links:

On December 18, 2025, Pyxis Oncology, Inc. announced positive preliminary data from its Phase 1 study for Micvotabart Pelidotin (MICVO) in head and neck cancer patients, reporting a 46% confirmed response rate. Additionally, the company completed a sale of royalty rights for $11 million to support MICVO's development.

AI Assistant

PYXIS ONCOLOGY INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.